SonoCloud

Low Intensity Contact Ultrasound Implant 

Clinical Developments

A phase 1/2a clinical trial is currently in progress to study the transient opening of the blood-brain barrier (BBB) using the SonoCloud® during chemotherapy administration in patients with recurrent glioblastoma.

This study is a prospective multidisciplinary single-arm mono-center study that is being performed by the departments of Neurosurgery and Neuro-Oncology at the Hospital Pitie Salpetriere. The study sponsor is l’Assistance Publique des Hôpitaux de Paris.

The study addresses patients with gliobastoma that have experienced recurrence after initial standard of care treatments and who are eligible for carboplatin chemotherapy. Patient inclusion is discussed on a case by case basis during multidisciplinary department meetings.

The goal of this Phase 1/2a clinical study is to temporarily disrupt the BBB using low intensity pulsed ultrasound during chemotherapy sessions with carboplatin, with the goal of increasing the concentration of chemotherapeutic agent in the brain tissue. Additional information is available on the site clinicaltrials.gov:

http://clinicaltrials.gov/ct2/show/NCT02253212?term=sonocloudrank=1

 

  • unnamed-2
    unnamed-3

     
  • News CarThera

    09.06.2018
    ASCO 2018: CarThera presents promising preliminary efficacy data for treating recurrent glioblastoma

    Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and promising trends in overall survival.

    Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) presented a preliminary analysis of the data from 21 glioblastoma patients who received 65 SonoCloud® treatments. Overall Survival was increased from 8.5 to 12.9 months in patients who had SonoCloud®-induced BBB opening.

    18.05.2018
    May 2018 – CarThera will participate to BIO 2018 in Boston

    CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

    Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at contact@carthera.eu and come to Booth 527 at the France Pavilion.

    03.07.2017
    CarThera presented data from phase 1/2a study at 2017 ASCO annual meeting

    June 2017 – Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) on ultrasound induced Blood-Brain Barrier opening revealed preliminary safety and efficacy data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

    The clinical data from the trial involving 21 patients with recurrent glioblastoma, who have all been treated with SonoCloud® low-intensity pulsed ultrasound in a total of 65 sessions, have been shared with more than 30,000 oncology professionals from around the world.